A
Agilent Technologies, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment comprises activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.
Market Cap: 27.4 Billion
Primary Exchange: New York Stock Exchange
Website: http://www.agilent.com
Shares Outstanding: 310 Million
Float: 308 Million
Dividend: 0.656 (0.01%)
Beta: 1.23834155954271
Sector: Health Technology
Industry: Biotechnology
Ethical Flags
Longest drawdown: 874 trading days
From: 2014-01-22 To: 2017-07-12
Lowest Point:
Barclays bearish on Teva, sees 14% downside risk in premarket analyst action
via: SeekingAlpha at 2019-06-11 04:46:44:000
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...
Barclays bearish on Teva, sees 14% downside risk in premarket analyst action
via: SeekingAlpha at 2019-06-11 04:46:44:000
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...
Barclays bearish on Teva, sees 14% downside risk in premarket analyst action
via: SeekingAlpha at 2019-06-11 04:46:44:000
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)
via: Business Wire at 2019-06-11 03:56:00:000
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)
via: Business Wire at 2019-06-11 03:56:00:000
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)
via: Business Wire at 2019-06-11 03:56:00:000
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|---|---|---|---|---|---|---|---|
| 2019-12-30 | 2020-01-22 | 2019-12-31 | 2019-11-20 | 0.18 | Cash | |||
| 2019-09-30 | 2019-10-23 | 2019-10-01 | 2019-09-18 | 0.164 | Cash | |||
| 2019-09-30 | 2019-10-23 | 2019-10-01 | 2019-09-18 | 0.164 | No Change QoQ | |||
| 2019-07-01 | 2019-07-24 | 2019-07-02 | 2019-05-22 | 0.164 | No Change QoQ | |||
| 2019-04-01 | 2019-04-24 | 2019-04-02 | 2019-03-20 | 0.164 | No Change QoQ | |||
| 2018-12-28 | 2019-01-23 | 2018-12-31 | 2018-11-14 | 0.164 | Increase | |||
| 2018-10-01 | 2018-10-24 | 2018-10-02 | 2018-09-19 | 0.149 | No Change QoQ | |||
| 2018-07-02 | 2018-07-25 | 2018-07-03 | 2018-05-16 | 0.149 | No Change QoQ | |||
| 2018-04-02 | 2018-04-25 | 2018-04-03 | 2018-03-21 | 0.149 | No Change QoQ | |||
| 2017-12-29 | 2018-01-24 | 2018-01-02 | 2017-11-15 | 0.149 | Increase | |||
| 2017-10-02 | 2017-10-25 | 2017-10-03 | 2017-09-20 | 0.132 | No Change QoQ | |||
| 2017-06-29 | 2017-07-26 | 2017-07-03 | 2017-05-17 | 0.132 | No Change QoQ | |||
| 2017-03-31 | 2017-04-26 | 2017-04-04 | 2017-03-15 | 0.132 | No Change QoQ | |||
| 2016-12-29 | 2017-01-25 | 2017-01-03 | 2016-11-17 | 0.132 | Increase | |||
| 2016-09-30 | 2016-10-26 | 2016-10-04 | 2016-09-21 | 0.115 | No Change QoQ | |||
| 2016-06-30 | 2016-07-27 | 2016-07-05 | 2016-05-18 | 0.115 | No Change QoQ | |||
| 2016-04-01 | 2016-04-27 | 2016-04-05 | 2016-03-16 | 0.115 | No Change QoQ | |||
| 2015-12-31 | 2016-01-27 | 2016-01-05 | 2015-11-19 | 0.115 | Increase | |||
| 2015-09-25 | 2015-10-21 | 2015-09-29 | 2015-09-16 | 0.1 | No Change QoQ | |||
| 2015-06-26 | 2015-07-22 | 2015-06-30 | 2015-05-20 | 0.1 | No Change QoQ | |||
| 2015-03-27 | 2015-04-22 | 2015-03-31 | 2015-03-18 | 0.1 | No Change QoQ | |||
| 2015-01-02 | 2015-01-28 | 2015-01-06 | 2014-11-20 | 0.1 | Decrease | |||
| 2014-09-26 | 2014-10-22 | 2014-09-30 | 2014-09-17 | 0.132 | No Change QoQ |
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|